Karyopharm Therapeutics Inc. (KPTI) has a consensus analyst rating of Buy, based on 20 analysts covering the stock. Of those, 14 recommend buying, 4 recommend holding, and 2 recommend selling.
The analyst consensus price target for KPTI is $14.17, representing a +65.5% upside from the current price of $8.56. Price targets range from a low of $6.00 to a high of $21.00.
